BIS
ProShares UltraShort Nasdaq Biotechnology [BIS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
BIS Stock Summary
Top 10 Correlated ETFs
BIS
Top 10 Correlated Stocks
BIS
In the News
BIS Financial details
Company Rating
-
Market Cap
3.1M
Income
-
Revenue
-
Book val./share
-
Cash/share
-
Dividend
0.11
Dividend %
1.88%
Employees
-
Optionable
No
Shortable
Yes
Earnings
-
P/E
0
Forward P/E
-
PEG
-
P/S
-
P/B
-
P/C
-
P/FCF
-
Quick Ratio
-
Current Ratio
-
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
1.82%
SMA50
-4.39%
SMA100
-24.24%
Inst Own
-
Inst Trans
-
ROA
-
ROE
-
ROC
-
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
16.37-26.51
52W High
-64.12%
52W Low
-41.69%
RSI
59.74
Rel Volume
0.63
Avg Volume
25.34K
Volume
16K
Perf Week
8.49%
Perf Month
5.9%
Perf Quarter
-31.6%
Perf Half Y
-33.02%
-
-
-
-
Beta
-1.27
-
-
Volatility
0.24%, 0.25%
Prev Close
0.86%
Price
9.33
Change
2.53%
BIS Financial Performance
BIS Frequently Asked Questions
What is ProShares UltraShort Nasdaq Biotechnology stock symbol ?
ProShares UltraShort Nasdaq Biotechnology is a US stock and trading under the symbol BIS
What is ProShares UltraShort Nasdaq Biotechnology stock quote today ?
ProShares UltraShort Nasdaq Biotechnology stock price is $9.33 today.
Is ProShares UltraShort Nasdaq Biotechnology stock public?
Yes, ProShares UltraShort Nasdaq Biotechnology is a publicly traded company.
Company Profile
- Volume Average 25.34K
- Market Capitalization 3.1M
- Headquarters US
- IPO Date 2010-04-09
The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the fund's investment objective. The index is a modified capitalization weighted index that includes securities of Nasdaq listed companies that are classified as either biotechnology or pharmaceutical. The fund is non-diversified.
